Abstract
DNA damage triggers cell death mechanisms contributing to neuronal loss and cognitive decline in neurological disorders, including traumatic brain injury (TBI), and as a side effect of chemotherapy. Mithramycin, which competitively targets chromatin-binding sites of specificity protein 1 (Sp1), was used to examine previously unexplored neuronal cell death regulatory mechanisms via rat primary neurons in vitro and after TBI in mice (males). In primary neurons exposed to DNA-damage-inducing chemotherapy drugs in vitro we showed that DNA breaks sequentially initiate DNA-damage responses, including phosphorylation of ATM, H2AX and tumor protein 53 (p53), transcriptional activation of pro-apoptotic BH3-only proteins, and mitochondrial outer membrane permeabilization (MOMP), activating caspase-dependent and caspase-independent intrinsic apoptosis. Mithramycin was highly neuroprotective in DNA-damage-dependent neuronal cell death, inhibiting chemotherapeutic-induced cell death cascades downstream of ATM and p53 phosphorylation/activation but upstream of p53-induced expression of pro-apoptotic molecules. Mithramycin reduced neuronal upregulation of BH3-only proteins and mitochondrial dysfunction, attenuated caspase-3/7 activation and caspase substrates’ cleavage, and limited c-Jun activation. Chromatin immunoprecipitation indicated that mithramycin attenuates Sp1 binding to pro-apoptotic gene promoters without altering p53 binding suggesting it acts by removing cofactors required for p53 transactivation. In contrast, the DNA-damage-independent neuronal death models displayed caspase initiation in the absence of p53/BH3 activation and were not protected even when mithramycin reduced caspase activation. Interestingly, experimental TBI triggers a multiplicity of neuronal death mechanisms. Although markers of DNA-damage/p53-dependent intrinsic apoptosis are detected acutely in the injured cortex and are attenuated by mithramycin, these processes may play a reduced role in early neuronal death after TBI, as caspase-dependent mechanisms are repressed in mature neurons while other, mithramycin-resistant mechanisms are active. Our data suggest that Sp1 is required for p53-mediated transactivation of neuronal pro-apoptotic molecules and that mithramycin may attenuate neuronal cell death in conditions predominantly involving DNA-damage-induced p53-dependent intrinsic apoptosis.
Highlights
Over 4 million people in the US are impacted by traumatic brain injury (TBI)[1] and almost 40% of patients demonstrate persistent functional decline[2]
To characterize mithramycin’s long-term neuroprotective effects, rat cortical neurons (RCN) were treated for 24 h followed by media replacement with RCN-conditioned media and further incubation until 48 or 72 h
We examined the effects of mithramycin on neuronal cell death pathways’ activation 24 h after controlled cortical impact (CCI)
Summary
Over 4 million people in the US are impacted by traumatic brain injury (TBI)[1] and almost 40% of patients demonstrate persistent functional decline[2]. TBI triggers multiple secondary injury processes leading to DNA damage and secondary central neurotoxicity may Official journal of the Cell Death Differentiation Association. The intrinsic apoptosis pathway initiated by DNA damage[9] involves p53 phosphorylation at serine 1510,11, followed by p53-dependent transcriptional activation of pro-apoptotic Bcl-2 family members[12,13]. These changes cause mitochondrial release[14,15] of pro-apoptotic molecules such as cytochrome c (CytC) and apoptosisinducing factor (AIF), leading to caspase-dependent and caspase-independent intrinsic apoptosis, respectively[10,15,16,17]. Total inhibition of p53 activities may be deleterious[25], and an effective long-term strategy requires a more selective modulation of p53’s transcriptional effects
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.